Sterling Investment Advisors (Pennsylvania)’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
Other funds holding NKTR
Sterling Investment Advisors (Pennsylvania)'s NKTR Position: Q3 2022 in Review
Sterling Investment Advisors (Pennsylvania) sold out of Nektar Therapeutics (NKTR) in Q3 2022, closing a stake of 37 shares — an estimated $2K sold.
Sterling Investment Advisors (Pennsylvania) first reported a position in NKTR in Q4 2016 and held it in 21 quarters. The position peaked at $183K in Q3 2018. 231 funds tracked by Wall St. Rank hold NKTR as of Q3 2022.
- Sterling Investment Advisors (Pennsylvania) reported no remaining Nektar Therapeutics position as of Q3 2022 after selling out during the quarter.
- Sterling Investment Advisors (Pennsylvania) sold 37 Nektar Therapeutics shares in Q3 2022, an estimated $2K.
- Sterling Investment Advisors (Pennsylvania) first reported a position in Nektar Therapeutics in Q4 2016 and held it in 21 quarters.
- Sterling Investment Advisors (Pennsylvania)'s Nektar Therapeutics position peaked at $183K in Q3 2018.
- 231 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2022.
Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q3 2022, filed 3 Nov 2022.